Aggressive and malignant prolactin pituitary tumors: Pathological diagnosis and patient management

Pituitary

Volumn 16, Issue 4, 2013, Pages 515-522

  Zemmoura, Ilyess ^a,b,f   Wierinckx, Anne ^c,d   Vasiljevic, Alexandre ^c,d,e   Jan, Michel ^a,b   Trouillas, Jacqueline ^c,d,e   François, Patrick ^a,b  

^a UNIVERSITY HOSPITAL OF TOURS   (France)

^b UNIVERSITÉ DE TOURS   (France)

^c LYON NEUROSCIENCE RESEARCH CENTER   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HOSPICES CIVILS DE LYON   (France)

^f CHU BRETONNEAU   (France)

Author keywords

Aggressive pituitary tumor; Classification; Hyperprolactinemia; Pituitary carcinoma; Prolactinoma

Indexed keywords

CABERGOLINE; KI 67 ANTIGEN; PROLACTIN; PROTEIN P53; QUINAGOLIDE; TRANSCRIPTION FACTOR ARNTL; TRANSCRIPTION FACTOR E2F2; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR PITX2; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1;

ADAMTS6 GENE; ADULT; AIP GENE; ALLELE; ARTICLE; ASK GENE; AURKB GENE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RESISTANCE; CASE REPORT; CCNB1 GENE; CENPE GENE; CHROMOSOME 11; CHROMOSOME LOSS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CRMP1 GENE; E2F2 GENE; E2F4 GENE; GAMMA KNIFE RADIOSURGERY; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PTX2 GENE; STEREOTACTIC BODY RADIATION THERAPY; TGFBETAR1 GENE; TUMOR INVASION; TUMOR VASCULARIZATION;

ANTINEOPLASTIC AGENTS; DOPAMINE AGONISTS; HUMANS; MALE; MIDDLE AGED; PITUITARY NEOPLASMS; PROLACTIN;

EID: 84888200777     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-012-0448-y     Document Type: Article

References (30)

1. Doniach I (1992) Pituitary carcinoma. Clin Endocrinol (Oxf) 37(2):194-195
2. Heaney AP (2011) Clinical review: pituitary carcinoma: difficult diagnosis and treatment. J Clin Endocrinol Metab 96(12):3649-3660. doi: 10.1210/jc.2011-2031
3. Kaltsas GA, Nomikos P, Kontogeorgos G, Buchfelder M, Grossman AB (2005) Clinical review: diagnosis and management of pituitary carcinomas. J Clin Endocrinol Metab 90(5):3089-3099. doi: 10.1210/jc.2004-2231
4. Scheithauer BW, Kovacs K, Horvath E et al (2004) Pituitary tumours: pituitary carcinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon, pp 36-39
5. Beauchesne P, Trouillas J, Barral F, Brunon J (1995) Gonadotropic pituitary carcinoma: case report. Neurosurgery 37(4):810-815 discussion 815-816
6. Gurlek A, Karavitaki N, Ansorge O, Wass JA (2007) What are the markers of aggressiveness in prolactinomas? Changes in cell biology, extracellular matrix components, angiogenesis and genetics. Eur J Endocrinol 156(2):143-153. doi: 10.1530/eje.1.02339
7. Kaltsas GA, Grossman AB (1998) Malignant pituitary tumours. Pituitary 1(1):69-81
8. Pernicone PJ, Scheithauer BW, Sebo TJ, Kovacs KT, Horvath E, Young WF Jr, Lloyd RV, Davis DH, Guthrie BL, Schoene WC (1997) Pituitary carcinoma: a clinicopathologic study of 15 cases. Cancer 79(4):804-812. doi: 10.1002/(SICI)1097-0142(19970215)79:4<804:AID-CNCR18>3.0.CO;2-3
9. Ragel BT, Couldwell WT (2004) Pituitary carcinoma: a review of the literature. Neurosurg Focus 16(4):E7
10. Scheithauer BW, Kurtkaya-Yapicier O, Kovacs KT, Young WF Jr, Lloyd RV (2005) Pituitary carcinoma: a clinicopathological review. Neurosurgery 56(5):1066-1074 discussion 1066-1074
11. Scheithauer BW, Gaffey TA, Lloyd RV, Sebo TJ, Kovacs KT, Horvath E, Yapicier O, Young WF Jr, Meyer FB, Kuroki T, Riehle DL, Laws ER Jr (2006) Pathobiology of pituitary adenomas and carcinomas. Neurosurgery 59(2):341-353. doi: 10.1227/01.NEU.0000223437.51435.6E discussion 341-353
12. Delgrange E, Sassolas G, Perrin G, Jan M, Trouillas J (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 147(7):751-757. doi: 10.1007/s00701-005-0498-2 discussion 757-758
13. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102-2107
14. Lloyd RV, Kovacs K, Young WF Jr et al (2007) Pituitary tumours: introduction. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) Tumours of the pituitary. World Health Organization Classification of tumours. Pathology and genetics of tumours of endocrine organs. IARC Press, Lyon, pp 10-13
15. Thapar K, Kovacs K, Scheithauer BW, Stefaneanu L, Horvath E, Pernicone PJ, Murray D, Laws ER Jr (1996) Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38(1):99-106 discussion 106-107
16. Cornelius A, Cortet-Rudelli C, Assaker R, Kerdraon O, Gevaert MH, Prevot V, Lassalle P, Trouillas J, Delehedde M, Maurage CA (2012) Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma. Brain Pathol 22(6):757-764. doi: 10.1111/j.1750-3639.2012.00578.x
17. Raverot G, Wierinckx A, Dantony E, Auger C, Chapas G, Villeneuve L, Brue T, Figarella-Branger D, Roy P, Jouanneau E, Jan M, Lachuer J, Trouillas J (2010) Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up. J Clin Endocrinol Metab 95(4):1708-1716. doi: 10.1210/jc.2009-1191
18. Wierinckx A, Auger C, Devauchelle P, Reynaud A, Chevallier P, Jan M, Perrin G, Fevre-Montange M, Rey C, Figarella-Branger D, Raverot G, Belin MF, Lachuer J, Trouillas J (2007) A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors. Endocr Relat Cancer 14(3):887-900. doi: 10.1677/ERC-07-0062
19. Pack SD, Qin LX, Pak E, Wang Y, Ault DO, Mannan P, Jaikumar S, Stratakis CA, Oldfield EH, Zhuang Z, Weil RJ (2005) Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization. Genes Chromosomes Cancer 43(1):72-82. doi: 10.1002/gcc.20162
20. Rickert CH, Dockhorn-Dworniczak B, Busch G, Moskopp D, Albert FK, Rama B, Paulus W (2001) Increased chromosomal imbalances in recurrent pituitary adenomas. Acta Neuropathol 102(6):615-620
21. Rickert CH, Scheithauer BW, Paulus W (2001) Chromosomal aberrations in pituitary carcinoma metastases. Acta Neuropathol 102(2):117-120
22. Wierinckx A, Roche M, Raverot G, Legras-Lachuer C, Croze S, Nazaret N, Rey C, Auger C, Jouanneau E, Chanson P, Trouillas J, Lachuer J (2011) Integrated genomic profiling identifies loss of chromosome 11p impacting transcriptomic activity in aggressive pituitary PRL tumors. Brain Pathol 21(5):533-543. doi: 10.1111/j.1750-3639.2011.00476.x
23. Hurel SJ, Harris PE, McNicol AM, Foster S, Kelly WF, Baylis PH (1997) Metastatic prolactinoma: effect of octreotide, cabergoline, carboplatin and etoposide; immunocytochemical analysis of proto-oncogene expression. J Clin Endocrinol Metab 82(9):2962-2965
24. Kars M, Roelfsema F, Romijn JA, Pereira AM (2006) Malignant prolactinoma: case report and review of the literature. Eur J Endocrinol 155(4):523-534. doi: 10.1530/eje.1.02268
25. Walker JD, Grossman A, Anderson JV, Ur E, Trainer PJ, Benn J, Lowy C, Sonksen PH, Plowman PN, Lowe DG et al (1993) Malignant prolactinoma with extracranial metastases: a report of three cases. Clin Endocrinol (Oxf) 38(4):411-419
26. Petterson T, MacFarlane IA, MacKenzie JM, Shaw MD (1992) Prolactin secreting pituitary carcinoma. J Neurol Neurosurg Psychiatry 55(12):1205-1206
27. Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105(4):621-626. doi: 10.3171/jns.2006.105.4. 621
28. Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7(6):518-520. doi: 10.1016/S1470-2045(06)70728-8
29. Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10(1):81-86. doi: 10.1007/s11102-007-0014-1
30. Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, Francois P, Jouanneau E, Passagia JG, Bernier M, Cornelius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95(10):4592-4599. doi: 10.1210/jc.2010-0644